How early-life colonization and subsequent exposure to the microbiota affect long-term tissue immunity remains poorly understood. Here, we show that the development of mucosal-associated invariant T (MAIT) cells relies on a specific temporal window, after which MAIT cell development is permanently impaired. This imprinting depends on early-life exposure to defined microbes that synthesize riboflavin-derived antigens. In adults, cutaneous MAIT cells are a dominant population of interleukin-17A (IL-17A)–producing lymphocytes, which display a distinct transcriptional signature and can subsequently respond to skin commensals in an IL-1–, IL-18–, and antigen-dependent manner. Consequently, local activation of cutaneous MAIT cells promotes wound healing. Together, our work uncovers a privileged interaction between defined members of the microbiota and MAIT cells, which sequentially controls both tissue-imprinting and subsequent responses to injury.

No abstract

No abstract

Over the last decade, our understanding of the composition and functions of the gut microbiota has greatly increased. To a large extent, this has been due to the development of high-throughput genomic analyses of microbial communities, which have identified the critical contributions of the microbiome to human health. Consequently, the intestinal microbiota has emerged as an attractive therapeutic target. The large majority of microbiota-targeted therapies aim at engineering the intestinal ecosystem by means of probiotics or prebiotics. Recently, a novel therapeutic approach has emerged which focuses on molecules that are secreted, modulated, or degraded by the microbiome and act directly on the host. Here, we discuss the advantages and challenges associated with the metabolite-based “postbiotic” approach, highlighting recent progress and the areas that need intensive attention and investigation over the next 5 years. The time is ripe for postbiotic therapies to be developed in the near future.

Resolution of leishmaniasis depends upon parasite control and limiting inflammation. CD4 Th1 cells are required to control parasites, whereas CD8 T cells play a dual role: they promote Th1 cell differentiation but can also increase inflammation at the site of infection as a consequence of cytolysis. Although CD8 T cells taken from leishmanial lesions are cytolytic, in this study, we showed that only a few CD8 T cells produced IFN-γ. Correspondingly, only low levels of IL-12 and/or IL-12 mRNA were present in lesions from infected mice, as well as patients. Addition of IL-12 increased IFN-γ production by CD8 T cells isolated from leishmanial lesions, suggesting that a lack of IL-12 at the site of infection limits IFN-γ production by CD8 T cells. To determine whether CD8 T cells could promote resistance in vivo if IL-12 was present, we administered IL-12 to -infected RAG mice reconstituted with CD8 T cells. IL-12 treatment increased the ability of CD8 T cells to make IFN-γ, but CD8 T cells still failed to control the parasites. Furthermore, despite the ability of CD8 T cells to promote immunity to secondary infections, we also found that CD8 T cells from immune mice were unable to control in RAG mice. Taken together, these results indicate that lesional CD8 T cells fail to make IFN-γ because of a deficit in IL-12 but that, even with IL-12, CD8 T cells are unable to control in the absence of CD4 T cells.